Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

* INCLUSION CRITERIA To be eligible to participate in this study, an individual must meet all of the following criteria: 1. Adults 18 to 65 years of age 2. BMI greater than or equal to 30 kg/m\^2 and less than or equal to 45 kg/m\^2 EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: 1. Hypersensitivity and associated allergic reactions to mirabegron or alpha-lipoic acid (or similar drug substances or components). 2. Abnormal bladder function, diagnosis of bladder outlet obstruction, urgency, and urinary frequency or use of antimuscarinic medication to treat overactive bladder (OAB). 3. Type 1 diabetes mellitus; type 2 diabetes mellitus; or any person taking exogenous insulin therapy or any medication that is a hypoglycemic agent. (type 1 or Type 2 Diabetes mellitus, fasting serum glucose \>125 mg/dL, and/or an HbA1c test \>6.5%). 4. Elevated resting blood pressure \>140/90 mmHg. 5. Individuals with eGFR \<60 ml/min/1.72 m\^2 and a urinary albumin/creatinine ratio UACR\>300 mg/g. 6. Hypo- or hyper-thyroid disease (TSH \>5.0, or \<0.4 MIU/L) that is controlled for less than one year or someone currently taking thyroid hormone replacement. 7. Anemia, defined by hemoglobin \<11.5 g/dL (females) or \<13.5 g/dL (males); sickle cell anemia or other blood disorders; and/or wound healing problems. 8. Cardiovascular disease, cardiac arrhythmias, orthostasis, unstable vasomotor system, or renal impairment. 9. A clinically significant abnormal ECG and/or QTc interval above normal 10. Moderate hepatic impairment (Child-Pugh Class B) or above 11. Elevated liver enzymes \>75 U/L (ALT or AST) 12. Recent history in last 4 weeks of any local or systemic infectious disease with fever or requiring antibiotics 13. Pregnancy, childbirth within the last year, or breastfeeding in the past 12 months. 14. Individuals that have been on a very low-calorie diet (\<800 kcal/d), self-reported weight loss \>5% in the preceding six months, or those taking weight loss medications. 15. History of seizure disorder. 16. Addiction to alcohol or substances of abuse within the last 5 years. 17. Self-reported current alcohol consumption of more than 2 servings of alcohol per day. 18. Self-reported current use of nicotine and/or tobacco products. 19. Current use of any drugs known to: 1. Have major drug-drug interactions with mirabegron or alpha-lipoic acid 2. Be CYP2D6 substrates 3. Prolong QT interval 4. Alter glucose metabolism or cause insulin resistance (in last six months) 5. Treat diabetes mellitus 6. Treat hypertension 7. Be drugs of abuse 20. Inability to provide informed consent. 21. Unwilling or unable to eat metabolic meals, as determined by dietitian consult. 22. Individuals with significant medical comorbidities or other factors that would render the individual s participation unsafe or affect the outcome of the study as assessed by the investigator.